MobiDrop, focusing on the innovation and development of microfluidic and single-cell sequencing technologies, will continue to create a diversified and efficient single-cell ecosystem with the fresh proceeds.
MobiDrop (Chinese: 墨卓生物) completed its Series A+ round of financing worth nearly CNY 100 million recently. This round was led by LYFE Capital（Chinese: 洲嶺资本), with the participation from the existing investors Source Code Capital (Chinese: 源码资本) and Yunxiang Funding (Chinese: 云祥基金).
The funding will be used to expand the company's single-cell R&D pipelines, promote the development of the high-throughput microbial single-cell genomics platform MobiMicrobe™ and continue to accelerate the development and commercialization of its products.
Founded in 2018 and driven by third-generation microfluidic technologies, MobiDrop is committed to empowering revolutionary advances in life sciences and precision medicine. The company develops advanced instruments, comprehensive assays, and easy-to-use software for ddPCR and single-cell multi-omic platforms. The company's core product is MobiNova-100 Single-Cell System.
The company's competitors include Shanghai Biochip (Chinese: 上海生物芯片), Annoroad (Chinese: 安诺优达) and Biomarker Technologies (Chinese: 百迈客生物).